173 related articles for article (PubMed ID: 18379015)
1. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Kabbara N; Lacroix C; Peffault de Latour R; Socié G; Ghannoum M; Ribaud P
Haematologica; 2008 Apr; 93(4):639-40. PubMed ID: 18379015
[No Abstract] [Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.
Girmenia C; Moleti ML; Micozzi A; Iori AP; Barberi W; Foà R; Martino P
J Clin Microbiol; 2005 Oct; 43(10):5395-6. PubMed ID: 16208029
[TBL] [Abstract][Full Text] [Related]
4. Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
Conen A; Weisser M; Jörg CO; Battegay M; Trampuz A; Frei R; Christen S; Heim D; Gratwohl A; Flückiger U
Transpl Infect Dis; 2008 Feb; 10(1):66-70. PubMed ID: 17511816
[TBL] [Abstract][Full Text] [Related]
5. Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
Morita K; Honda A; Koya J; Toyama K; Ikeda M; Misawa Y; Okugawa S; Nakamura F; Moriya K; Kurokawa M
J Infect Chemother; 2018 Jul; 24(7):576-578. PubMed ID: 29371065
[TBL] [Abstract][Full Text] [Related]
6. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Jantunen E; Nihtinen A; Volin L; Juvonen E; Parkkali T; Ruutu T; Anttila VJ
Bone Marrow Transplant; 2004 Nov; 34(10):891-5. PubMed ID: 15517009
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
McGee WT; Tereso GJ
Crit Care Med; 2003 May; 31(5):1577-8. PubMed ID: 12771636
[TBL] [Abstract][Full Text] [Related]
8. Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.
van Hal SJ; Stark D; Harkness J; Marriott D
Emerg Infect Dis; 2008 Feb; 14(2):327-9. PubMed ID: 18258133
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
10. Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin.
Fanci R; Guidi S; Bonolis M; Bosi A
Bone Marrow Transplant; 2005 Jun; 35(12):1215-6. PubMed ID: 15852027
[No Abstract] [Full Text] [Related]
11. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest GN; Weekes E; Johnson JK
J Infect; 2008 Feb; 56(2):126-9. PubMed ID: 18082269
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Garcia-Effron G; Kontoyiannis DP; Lewis RE; Perlin DS
Antimicrob Agents Chemother; 2008 Nov; 52(11):4181-3. PubMed ID: 18794386
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
Clancy CJ; Staley B; Nguyen MH
Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
[TBL] [Abstract][Full Text] [Related]
14. Candida norvegensis fungemia in a liver transplant recipient.
Sanclemente G; Marco F; Cervera C; Hoyo I; Colmenero J; Pitart C; Almela M; Navasa M; Moreno A
Rev Iberoam Micol; 2015; 32(2):115-7. PubMed ID: 24794213
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
16. [Role of anidulafungin in solid organ transplant recipients].
Aguado JM; Ayats J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():29-34. PubMed ID: 19572432
[TBL] [Abstract][Full Text] [Related]
17. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole.
Jarque I; Saavedra S; Martin G; Pemán J; Pérez Bellés C; Sanz MA
Haematologica; 2000 Apr; 85(4):441-3. PubMed ID: 10757896
[No Abstract] [Full Text] [Related]
18. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.
Natale F; Castronovo A; Regoli D; De Curtis M; Manzoni P
Pediatr Infect Dis J; 2009 May; 28(5):452. PubMed ID: 19295457
[No Abstract] [Full Text] [Related]
19. Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
Gahn B; Schub N; Repp R; Gramatzki M
Eur J Med Res; 2007 Aug; 12(8):337-40. PubMed ID: 17933709
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.
Krcmery V; Demitrovicova A; Kisac P
J Chemother; 2011 Oct; 23(5):310-1. PubMed ID: 22005067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
